ReviewClinical transplantation and research2025
Fibromuscular dysplasia and living kidney donors: a narrative review.
Review in Clinical transplantation and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To address the shortage of grafts, renal transplant teams actively utilize all available donation options, including those that challenge the conventional criteria for living donors. However, this approach may involve situations requiring careful assessment of specific risks-particularly those that could jeopardize donor safety, expose the recipient or graft to vascular complications associated with certain arterial reconstructions, or threaten graft function in the recipient. Kidney donation in the context of fibromuscular dysplasia represents one such scenario, as this condition encompasses all three of these risks. Transplant centers that do not automatically exclude such donations recommend a selective approach, with decisions to accept these kidneys made on a case-by-case basis through evaluation by multidisciplinary teams comprising nephrologists, angiologists, and transplant surgeons. This narrative review aims to provide an update on (1) the identification and assessment of this arterial lesion during predonation evaluation, (2) the acceptability criteria for kidneys affected by fibromuscular dysplasia, (3) the safety and long-term outcomes for donors following nephrectomy, and (4) technical considerations for transplanting these grafts and their outcomes in recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.